---
schema_version: "secwatch.filing_event.v1"
accession: "0001724521-23-000018"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T16:26:55.555158+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Arcus Biosciences Q3 net loss $71M; cash $950M; domvanalimab and AB521 updates

## Summary
- Net loss of $71M in Q3 2023 vs $65M in Q3 2022; R&D expenses rose to $82M from $77M.
- Cash, cash equivalents and marketable securities $950M as of Sept 30, 2023, down from $1.1B at Dec 31, 2022; cash runway into 2026.
- Revenue $32M in Q3 2023, primarily from Gilead collaboration, vs $33M in Q3 2022.
- EDGE-Gastric Phase 2: domvanalimab + zimberelimab + chemo showed 80% ORR in PD-L1-high tumors; maturity PFS data expected H2 2024.
- AB521 Phase 1/1b: PK/PD consistent with healthy volunteers; no DLTs; ccRCC dose-expansion near completion; efficacy data later in 2024.

## SEC filing metadata
- accession: 0001724521-23-000018
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000172452123000018/0001724521-23-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000172452123000018/rcus-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001724521-23-000018
- JSON: https://secwatch.observer/filing/0001724521-23-000018.json
- Plain text: https://secwatch.observer/filing/0001724521-23-000018.txt

## Key facts
- Earnings Releases
  Arcus Biosciences, Inc. reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 7, 2023 , Arcus Biosciences, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1724521/000172452123000018/0001724521-23-000018-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.